Stock Analiz

Arcus Biosciences, Inc. (RCUS) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Net income in fiscal 2025 was -$353M, a net margin of -142.9%; the best year in this period was 2021 with $53M.

Over the twelve months to September 30, 2026, revenue was $100M and net income -$453M.

Free cash flow was -$484M in fiscal 2025 and positive in 2 of the 10 years shown.

The diluted share count rose 12331% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2017: $1M172018: $8M182019: $15M192020: $78M202021: $383M212022: $112M222023: $117M232024: $258M242025: $247M25$247M
Net income
2016: -$18M162017: -$53M172018: -$50M182019: -$85M192020: -$123M202021: $53M212022: -$267M222023: -$307M232024: -$283M242025: -$353M25-$353M
Free cash flow
2016: -$17M162017: -$31M172018: -$47M182019: -$75M192020: $108M202021: -$282M212022: $432M222023: -$330M232024: -$176M242025: -$484M25-$484M
EPS (diluted)
2016: $-20.80162017: $-29.03172018: $-1.43182019: $-1.93192020: $-2.24202021: $0.71212022: $-3.71222023: $-4.15232024: $-3.14242025: $-3.2925$-3.29

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$100M$247M$258M$117M$112M$383M$78M$15M$8M$1M—
Gross profit———————————
Operating income-$475M-$386M-$330M-$340M-$280M$54M-$124M-$89M-$55M-$53M-$18M
Net income-$453M-$353M-$283M-$307M-$267M$53M-$123M-$85M-$50M-$53M-$18M
EPS (diluted)$-3.64$-3.29$-3.14$-4.15$-3.71$0.71$-2.24$-1.93$-1.43$-29.03$-20.80
R&D$473M$523M$448M$340M$288M$257M$159M$78M$50M$47M$14M
Revenue growth—−4.3%+120.5%+4.5%−70.8%+391.0%+420.0%+79.6%+491.2%——

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow-$465M-$482M-$170M-$306M$438M-$256M$111M-$73M-$43M-$25M-$13M
Capital spending-$1M-$2M-$6M-$24M-$6M-$26M-$3M-$2M-$4M-$6M-$4M
Free cash flow-$466M-$484M-$176M-$330M$432M-$282M$108M-$75M-$47M-$31M-$17M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————$94000$0——
Stock-based pay$65M$60M$76M$73M$65M$55M$22M$9M$4M$495000$90000

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$981M$978M$759M$1.0B$499M$729M$58M$71M$98M$65M
Debt—$198M$159M$121M$126M$114M$18M————
Equity—$631M$485M$462M$657M$842M$502M$164M$235M-$72M-$20M
Total assets—$1.1B$1.1B$1.1B$1.3B$1.6B$772M$203M$275M$190M—
Shares (diluted)127M107M90M74M72M74M55M44M35M2M1M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin———————————
Operating margin-475.0%-156.3%-127.9%-290.6%-250.0%14.1%-159.0%-591.4%-656.8%-3782.1%—
Net margin-453.0%-142.9%-109.7%-262.4%-238.4%13.8%-157.7%-564.7%-593.7%-3756.7%—
FCF margin-466.0%-195.9%-68.2%-282.1%385.7%-73.6%138.5%-502.6%-559.6%-2163.7%—
ROIC—-46.6%-40.5%-46.1%-28.2%5.5%-18.8%-42.7%-18.4%——
ROE—-55.9%-58.4%-66.5%-40.6%6.3%-24.5%-51.6%-21.1%73.4%89.9%

Frequently asked questions

What is Arcus Biosciences’s annual revenue?

$247M in fiscal 2025 and $100M over the twelve months to September 30, 2026.

How much profit does Arcus Biosciences make?

Net income was -$353M in fiscal 2025 (net margin -142.9%).

Is Arcus Biosciences’s revenue growing?

No: revenue fell 4.3% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.